ABSTRACT
This study was performed to evaluate the relationship between the CHA2DS2-VASc score and no-reflow (NR) phenomena in patients with non-ST-segment elevation myocardial infarction (NSTEMI). A total number of 428 consecutive patients with NSTEMI were assessed for this study. Patients were divided into 2 groups, those with NR, NR(+) (n=84), and those without NR, NR(-) (n=307), according to their post-PCI, no-reflow status. The CHA2DS2-VASc score was significantly higher in the NR(+) group compared to the NR(-) (3.48 ± 1.19 vs 1.81 ± 0.82, P < 0.001). After a multivariate regression analysis, a higher CHA2DS2-VASc score (OR: 6.52, 95% CI: 3.51-12.14, P < 0.001), hs-Troponin (OR: 1.077, 95% CI: 1.056-1.099, P< 0.001) and TTG (OR: 1.563, 95% CI: 1.134-2.154, P=0.006) were independent predictors of NR. CHA2DS2-VASc score is associated with higher risk of no-reflow in patients with NSTEMI undergoing PCI.
